Dyne pivots on primary endpoint, delays filing for DM1 drugnews2025-06-17T14:44:22+00:00June 17th, 2025|Endpoints News|
Immuneering reports Phase 2a MEK pill data in first-line pancreatic cancernews2025-06-17T10:00:19+00:00June 17th, 2025|Endpoints News|
Fired vaccine advisors defend ACIP’s work in joint editorialnews2025-06-17T01:16:21+00:00June 17th, 2025|Endpoints News|
AbbVie’s Venclexta fails Phase 3 study in other bone marrow cancersnews2025-06-16T15:25:26+00:00June 16th, 2025|Endpoints News|
Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial resultsnews2025-06-16T14:55:51+00:00June 16th, 2025|Endpoints News|
Lilly posts encouraging early-stage weight loss data on amylin candidatenews2025-06-16T10:44:04+00:00June 16th, 2025|Endpoints News|
#EHA25: Gilead, Arcellx continue to tout safety of multiple myeloma cell therapy anito-celnews2025-06-16T08:48:16+00:00June 16th, 2025|Endpoints News|
Sarepta halts Duchenne gene therapy in some patients after second deathnews2025-06-16T02:18:20+00:00June 16th, 2025|Endpoints News|
AstraZeneca, CSPC ink AI drug development deal for $110M upfront news2025-06-13T10:58:25+00:00June 13th, 2025|Endpoints News|
Novo Nordisk plans Phase 3 trials of oral, injectable amycretinnews2025-06-12T19:00:27+00:00June 12th, 2025|Endpoints News|
